High Prevalence of Skin Disorders among HTLV-1 Infected Individuals Independent of Clinical Status

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author OKAJIMA, Renata FMUSP-HC
OLIVEIRA, Augusto C. P.
SMID, Jerusa
CASSEB, Jorge FMUSP-HC
SANCHES JR., Jose Antonio FMUSP-HC
dc.date.issued 2013
dc.identifier.citation PLOS NEGLECTED TROPICAL DISEASES, v.7, n.11, article ID e2546, 5p, 2013
dc.identifier.issn 1935-2735
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/5119
dc.description.abstract Background: Human T-cell lymphotropic virus type 1 (HTLV-1) infection can increase the risk of developing skin disorders. This study evaluated the correlation between HTLV-1 proviral load and CD4(+) and CD8(+) T cells count among HTLV-1 infected individuals, with or without skin disorders (SD) associated with HTLV-1 infection [SD-HTLV-1: xerosis/ichthyosis, seborrheic dermatitis or infective dermatitis associated to HTLV-1 (IDH)]. Methods: A total of 193 HTLV-1-infected subjects underwent an interview, dermatological examination, initial HTLV-1 proviral load assay, CD4(+) and CD8(+) T cells count, and lymphproliferation assay (LPA). Results: A total of 147 patients had an abnormal skin condition; 116 (79%) of them also had SD-HTLV-1 and 21% had other dermatological diagnoses. The most prevalent SD-HTLV-1 was xerosis/acquired ichthyosis (48%), followed by seborrheic dermatitis (28%). Patients with SD-HTLV-1 were older (51 vs. 47 years), had a higher prevalence of myelopathy/tropical spastic paraparesis (HAM/TSP) (75%), and had an increased first HTLV-1 proviral load and basal LPA compared with patients without SD-HTLV-1. When excluding HAM/TSP patients, the first HTLV-1 proviral load of SD-HTLV-1 individuals remains higher than no SD-HTLV-1 patients. Conclusions: There was a high prevalence of skin disorders (76%) among HTLV-1-infected individuals, regardless of clinical status, and 60% of these diseases are considered skin disease associated with HTLV-1 infection.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa o Estado de Sao Paulo (FAPESP) [2008/56427-4]
dc.language.iso eng
dc.publisher PUBLIC LIBRARY SCIENCE
dc.relation.ispartof Plos Neglected Tropical Diseases
dc.rights openAccess
dc.subject.other myelopathy/tropical spastic paraparesis; lymphotropic virus type-1; i-associated myelopathy; proviral load; dermatological lesions; peripheral-blood; dermatitis; marker; disease
dc.title High Prevalence of Skin Disorders among HTLV-1 Infected Individuals Independent of Clinical Status
dc.type article
dc.rights.holder Copyright PUBLIC LIBRARY SCIENCE
dc.description.group LIM/53
dc.description.group LIM/56
dc.identifier.doi 10.1371/journal.pntd.0002546
dc.identifier.pmid 24244779
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author OKAJIMA, Renata:FM:
hcfmusp.author CASSEB, Jorge:HC:ICHC
hcfmusp.author SANCHES JR., Jose Antonio:FM:MDT
hcfmusp.author.external · OLIVEIRA, Augusto C. P.:Inst Infect Dis Emilio Ribas, HTLV Outpatient Clin, Sao Paulo, Brazil
· SMID, Jerusa:Inst Infect Dis Emilio Ribas, HTLV Outpatient Clin, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000330378400029
hcfmusp.origem.id 2-s2.0-84888252740
hcfmusp.publisher.city SAN FRANCISCO
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Alamy AH, 2001, ANN NEUROL, V50, P681, DOI 10.1002/ana.1264
· Bittencourt AL, 2010, INT J DERMATOL, V49, P1099, DOI 10.1111/j.1365-4632.2010.04568.x
· Carneiro-Proietti Anna Bárbara F, 2002, Rev Soc Bras Med Trop, V35, P499, DOI 10.1590/S0037-86822002000500013
· Catalan-Soares Bernadette, 2005, Cad Saude Publica, V21, P926, DOI 10.1590/S0102-311X2005000300027
· Furtado MDBS, 2012, J MED VIROL, V84, P664, DOI 10.1002/jmv.23227
· Gessain A, 2012, FRONT MICROBIOL, V3, P1
· Goncalves DU, 2003, AM J TROP MED HYG, V68, P562
· Hashiguchi T OM, 1989, HTLV 1 NERVOUS SYSTE, P443
· Ijichi S, 1996, J ACQ IMMUN DEF SYND, V13, pS26, DOI 10.1097/00042560-199600001-00006
· KAWAI H, 1992, J MED VIROL, V38, P138, DOI 10.1002/jmv.1890380212
· LAGRENADE L, 1990, LANCET, V336, P1345
· Lezin A, 2005, J INFECT DIS, V191, P1830, DOI 10.1086/429962
· McGill NK, 2012, EXP DERMATOL, V21, P815, DOI 10.1111/exd.12007
· Milagres SP, 2003, BRIT J DERMATOL, V149, P776, DOI 10.1046/j.1365-2133.2003.05567.x
· Mochizuki M, 1996, J ACQ IMMUN DEF SYND, V13, pS50, DOI 10.1097/00042560-199600001-00010
· Montanheito PA, 2005, BRAZ J MED BIOL RES, V38, P1643, DOI 10.1590/S0100-879X2005001100011
· Nobre V, 2005, REV SOC BRAS MED TRO, V38, P43, DOI 10.1590/S0037-86822005000100009
· Novoa P, 2007, J MED VIROL, V79, P182, DOI 10.1002/jmv.20775
· Olindo S, 2005, J NEUROL SCI, V237, P53, DOI 10.1016/j.jns.2005.05.010
· OSAME M, 1986, LANCET, V1, P1031
· POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415
· Primo J, 2009, BRAZ J MED BIOL RES, V42, P761, DOI 10.1590/S0100-879X2009005000008
· Setoyama M, 1998, AM J PATHOL, V152, P683
dc.description.index MEDLINE
hcfmusp.citation.scopus 11
hcfmusp.citation.wos 10
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics